November 1, 2012

The heated 2012 Presidential Campaign has finally come to an end and the focus has shifted from politics to policy. What effect will the outcome have on the future of pharmaceutical and medical device manufacturers? One thing is certain — manufacturers will need to demonstrate economic and clinical value for their products.

In the article The Impact of the 2012 Election Is All About Product Value, published in FierceBiotech November 2012, NAI President Rita E. Numerof, Ph.D. explains how manufacturers will face stricter regulation and will be required to demonstrate more solid evidence to support their products, both pre-market and post-market. She also offers her insights into specific actions that will need to be taken by manufacturers to ensure success moving forward.